Evidence map›Paper›PMID 39067017›Full record

ArticleBioinformatics (Oxford, England)2024

Best practices to evaluate the impact of biomedical research software-metric collection beyond citations.

Awan Afiaz, Andrey A Ivanov, John Chamberlin, David Hanauer, Candace L Savonen, Mary J Goldman, Martin Morgan, Michael Reich, Alexander Getka, Aaron Holmes and 17 more

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Awan AfiazDepartment of Biostatistics, University of Washington, Seattle, WA, 98195, United States.ORCID 0000-0001-5801-9087
Andrey A IvanovDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Emory University, Atlanta , GA, 30322, United States.ORCID 0000-0001-7476-1329
John ChamberlinDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT, 84108, United States.
David HanauerDepartment of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Candace L SavonenBiostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.
Mary J GoldmanUC Santa Cruz Genomics Institute, University of California Santa Cruz, Santa Cruz, CA, 95060, United States.
Martin MorganRoswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, United States.
Michael ReichUniversity of California, San Diego, La Jolla, CA, 92093, United States.
Alexander GetkaUniversity of Pennsylvania, Philadelphia, PA, 19104, United States.
Aaron HolmesJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, 90095, United States.
Sarthak PatiUniversity of Pennsylvania, Philadelphia, PA, 19104, United States.ORCID 0000-0003-2243-8487
Dan KnightJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, 90095, United States.
Paul C BoutrosJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, 90095, United States.ORCID 0000-0003-0553-7520
Spyridon BakasUniversity of Pennsylvania, Philadelphia, PA, 19104, United States.
J Gregory CaporasoPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, 86011, United States.
Guilherme Del FiolDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT, 84108, United States.ORCID 0000-0001-9954-6799
Harry HochheiserDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, United States.ORCID 0000-0001-8793-9982
Brian HaasMethods Development Laboratory, Broad Institute, Cambridge, MA, 02141, United States.
Patrick D SchlossDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, 48109, United States.
James A EddySage Bionetworks, Seattle, WA, 98121, United States.
Jake AlbrechtSage Bionetworks, Seattle, WA, 98121, United States.
Andrey FedorovDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02138, United States.
Levi WaldronDepartment of Epidemiology and Biostatistics, City University of New York Graduate School of Public Health and Health Policy, New York, NY, 10027, United States.ORCID 0000-0003-2725-0694
Ava M HoffmanBiostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.ORCID 0000-0002-1833-4397
Richard L BradshawDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT, 84108, United States.ORCID 0000-0001-7363-0327
Jeffrey T LeekBiostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.
Carrie WrightBiostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.ORCID 0000-0003-1325-6067

Funding

Tool Core- BoutrosU54HG012517 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, PING, PEIPEI · 2022 to 2025
$10.6M
Cancer Genomics:Integrative and Scalable Solutions in R / BioconductorU24CA180996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T, WALDRON, LEVI · 2014 to 2023
$6.9M
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1M
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resourcesU24CA258407 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HAUSSLER, DAVID H, ZHU, JINGCHUN · 2021 to 2025
$3.8M
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)U24CA248454 · NCI · NORTHERN ARIZONA UNIVERSITY · PI CAPORASO, JAMES GREGORY · 2020 to 2024
$3.7M
Scalable multi-mode education to increase use of ITCR tools by diverse analystsUE5CA254170 · NCI · JOHNS HOPKINS UNIVERSITY · PI GRIFFITH, MALACHI, GRIFFITH, OBI L. · 2020 to 2024
$3.6M
Privacy-Aware Federated Learning for Breast Cancer Risk AssessmentU24CA279629 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Spyridon Bakas · 2023 to 2026
$2.9M
Data analysis tools for leveraging massive public data to improve hypothesis-driven researchR35GM144128 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Jeffrey T. Leek · 2022 to 2026
$2.2M
Enhance UCSC Xena Browser to Visualize Single Cell Cancer Moonshot dataR33CA263703 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI ZHU, JINGCHUN · 2021 to 2021
$1.5M
The Federated Tumor Segmentation (FeTS) platform: An intuitive tool facilitating secure multi-institutional collaborationU01CA242871 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BAKAS, SPYRIDON · 2019 to 2021
$1.1M
Predicting actionable cancer vulnerabilities enabled by mutant-directed protein-protein interactionsR21CA274620 · NCI · EMORY UNIVERSITY · PI IVANOV, ANDREY · 2022 to 2023
$398k
NCI NIH HHS R21 CA274620NCI NIH HHS R33 CA263703NCI NIH HHS U01 CA242871NCI NIH HHS U24 CA180996NCI NIH HHS U24 CA248265NCI NIH HHS U24 CA248454NCI NIH HHS U24 CA258407NCI NIH HHS U24 CA279629NCI NIH HHS UE5 CA254170NHGRI NIH HHS U54 HG012517NIGMS NIH HHS R35 GM144128NIH HHS
6 · The paper itself

Abstract

motivationSoftware is vital for the advancement of biology and medicine. Impact evaluations of scientific software have primarily emphasized traditional citation metrics of associated papers, despite these metrics inadequately capturing the dynamic picture of impact and despite challenges with improper citation.

resultsTo understand how software developers evaluate their tools, we conducted a survey of participants in the Informatics Technology for Cancer Research (ITCR) program funded by the National Cancer Institute (NCI). We found that although developers realize the value of more extensive metric collection, they find a lack of funding and time hindering. We also investigated software among this community for how often infrastructure that supports more nontraditional metrics were implemented and how this impacted rates of papers describing usage of the software. We found that infrastructure such as social media presence, more in-depth documentation, the presence of software health metrics, and clear information on how to contact developers seemed to be associated with increased mention rates. Analysing more diverse metrics can enable developers to better understand user engagement, justify continued funding, identify novel use cases, pinpoint improvement areas, and ultimately amplify their software's impact. Challenges are associated, including distorted or misleading metrics, as well as ethical and security concerns. More attention to nuances involved in capturing impact across the spectrum of biomedical software is needed. For funders and developers, we outline guidance based on experience from our community. By considering how we evaluate software, we can empower developers to create tools that more effectively accelerate biological and medical research progress. AVAILABILITY AND IMPLEMENTATION: More information about the analysis, as well as access to data and code is available at https://github.com/fhdsl/ITCR_Metrics_manuscript_website.

Indexed as

Biomedical ResearchSoftwareComputational BiologyHumansUnited States

Identifiers

PMID39067017
PMCPMC11297485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.